May 14th 2025
Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.
Watch the series now!
Kentucky's New Governor Could Change the Terms of Medicaid Expansion
Dr Lee Newcomer on Value Calculators and New Immuno-Oncology Agents
Ted Okon Outlines the Purpose of COA's Payer Exchange Summit